Skip to main content
SpringerLink
Log in

Antipsychotics (Neuroleptics)

  • Chapter
Practitioner’s Guide to Psychoactive Drugs for Children and Adolescents

Abstract

Antipsychotic drugs are a large group of psychoactive agents mainly known for their antipsychotic clinical properties, though they are also effective in a variety of nonpsychotic disorders. Formerly, these drugs were called neuroleptics, because of their special sedative property.1

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Delay J, Deniker P: 38 cas de psychoses traitées par la cure prolongée et continue de 4560 RP-CR. 50iéme Congres des Alien et Neurologique de Langue Francaise, Luxembourg, 21-27 July, 1952, p 503.

    Google Scholar 

  2. Davis JM, Barter JT, Kane JM: Antipsychotic drugs, in Kaplan HI, Sadock BJ (eds): Comprehensive Textbook of Psychiatry, ed 5. Baltimore, Williams & Wilkins, 1989, vol II, pp 1591–1621.

    Google Scholar 

  3. Deutsch SI, Campbell M: Relative affinities for different classes of neurotransmitter receptors predict neuroleptic efficacy in infantile autism: A hypothesis. Neuropsychobiology 15: 160–164, 1986.

    PubMed  CAS  Google Scholar 

  4. Davis KL, Kahn RS, Ko G, et al: Dopamine in schizophrenia. A review and reconceptualization. Am J Psychiatry 148: 1474–1486, 1991.

    PubMed  CAS  Google Scholar 

  5. Sokoloff P, Giros B, Martres MP, et al: Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347: 146–159, 1990.

    PubMed  CAS  Google Scholar 

  6. Gould RJ, Murphy KMM, Reynolds IJ, et al: Antischizophrenic drugs of the diphenylbutylpiperidine type act as calcium channel antagonists. Proc Natl Acad Sci USA 80: 5122–5125, 1983.

    PubMed  CAS  Google Scholar 

  7. Peroutka SJ, Snyder SH: Relationship of neuroleptic drug effects at brain dopamine, serotonin, α-adrenergic, and histamine receptors to clinical potency. Am J Psychiatry 137: 1518–1522, 1980.

    PubMed  CAS  Google Scholar 

  8. Richelson E: Neuroleptic affinities for human brain receptors and their use in predicting adverse effects. J Clin Psychiatry 45: 331–336, 1984.

    PubMed  CAS  Google Scholar 

  9. Ernst M, Magee HJ, Gonzalez NM, et al: Pimozide in autistic children. Psychopharmacol Bull 28: 187–191, 1992.

    PubMed  CAS  Google Scholar 

  10. Geller B: Psychopharmacology of children and adolescents: Pharmacokinetics and relationships of plasma/serum levels to response. Psychopharmacol Bull 27(4): 401–409, 1991.

    PubMed  CAS  Google Scholar 

  11. Furlanut M, Benetello P, Baraldo M, et al: Chlorpromazine disposition in relation to age in children. Clin Pharmacokinet 18: 329–331, 1990.

    PubMed  CAS  Google Scholar 

  12. Morselli PL, Bianchetti G, Durand G, et al: Haloperidol plasma level monitoring in pediatric patients. Ther Drug Monitor 1: 35–46, 1979.

    CAS  Google Scholar 

  13. Poland RE, Campbell M, Rubin RT, et al: Relationship of serum haloperidol levels and clinical response in autistic children. Paper presented at the 13th CINP Congress (Collegium Internationale Psychopharmacologicum), Jerusalem, June 20-25, 1982.

    Google Scholar 

  14. Rivera-Calimlin L, Griesbach PH, Perlmutter R: Plasma chlorpromazine concentrations in children with behavioral disorders and mental illness. Clin Pharmacol Ther 26: 114–121, 1979.

    Google Scholar 

  15. Campbell M, Poland RE, Perry R, et al: Serum haloperidol levels and prolactin levels and clinical response in autistic children. Paper presented at the 35th Annual Meeting of the American Academy of Child and Adolescent Psychiatry with the Canadian Academy of Child Psychiatry, Seattle, October 27, 1988.

    Google Scholar 

  16. Gittelman-Klein R, Klein DF, Katz S, et al: Comparative effects of methylphenidate and thioridazine in hyperkinetic children: I. Clinical results. Arch Gen Psychiatry 33: 1217–1231, 1976.

    PubMed  CAS  Google Scholar 

  17. Rivera-Calimlin L, Nasrallah H, Strauss J, et al: Clinical response and plasma levels: Effect of dose, dosage, schedules, and drug interactions on plasma chlorpromazine levels. Am J Psychiatry 133: 646–652, 1976.

    Google Scholar 

  18. Geller B, Cooper TB, Farooki ZQ, et al: Dose and plasma levels of nortriptyline and chlorpromazine in delusionally depressed adolescents and of nortriptyline in nondelusionally depressed adolescents. Am J Psychiatry 142: 336–338, 1985.

    PubMed  CAS  Google Scholar 

  19. Diagnostic and Statistical Manual of Mental Disorders, ed 3 rev (DSM-III-R). Washington, DC, American Psychiatric Association Press, 1987.

    Google Scholar 

  20. Diagnostic and Statistical Manual of Mental Disorders, ed 3 (DSM-III). Washington, DC, American Psychiatric Association Press, 1980.

    Google Scholar 

  21. International Classification of Diseases ICD-9. Manual of the International Statistical Classification of Diseases, Injuries and Causes of Death. Geneva, World Health Organization, 1977, vol 1.

    Google Scholar 

  22. Thompson JW, Green D, Savit HL: Preliminary report on a crosswalk from DSM-III to ICD-9-CM. Am J Psychiatry 140: 176–180, 1983.

    PubMed  CAS  Google Scholar 

  23. Physicians Desk Reference, ed 46. Oradell, NJ, Medical Economics, 1992.

    Google Scholar 

  24. Simpson GM: Pharmacology and treatment of the major psychoses. Paper presented at the 30th Annual Meeting of the American College of Neuropsychopharmacology. San Juan, Puerto Rico, December 9-13, 1991.

    Google Scholar 

  25. Abnormal Involuntary Movements Scale. Psychopharmacol Bull 21(4): 1077–1080, 1985.

    Google Scholar 

  26. Campbell M: Protocol for rating drug-related AIMS, stereotypies and CPRS assessments. Psychopharmacol Bull Spec Feature 21(4): 1081, 1985.

    Google Scholar 

  27. Campbell M, Palij M: Measurement of untoward effects including tardive dyskinesia. Psychopharmacol Bull 21(4): 1063–1082, 1985.

    PubMed  CAS  Google Scholar 

  28. Campbell M, Spencer EK, Kowalik SC, et al: Schizophrenic and psychotic disorders, in Wiener JM (ed): Textbook of Child and Adolescent Psychiatry. Washington, DC, American Psychiatric Association Press, 1991, pp 223–239.

    Google Scholar 

  29. Spencer EK, Kafantaris V, Padron-Gayol M, et al: Haloperidol in schizophrenic children: Early findings from a study in progress. Psychopharmacol Bull, 28(2): 183–186, 1992.

    PubMed  CAS  Google Scholar 

  30. Pool D, Bloom W, Mielke DH, et al: A controlled evaluation of loxitane in seventy-five adolescent schizophrenic adolescents. Curr Ther Res 19: 99–104, 1976.

    PubMed  CAS  Google Scholar 

  31. Realmuto GM, Ekickson WD, Yellin A, et al: Clinical comparison of thiothixene and thioridazine in schizophrenic adolescents. Am J Psychiatry 141: 440–442, 1984.

    PubMed  CAS  Google Scholar 

  32. Kane J, Honigfeld G, Singfer J, et al: Clozapine for the treatment resistant schizophrenic. Arch Gen Psychiatry 45: 789–796, 1988.

    PubMed  CAS  Google Scholar 

  33. Siefen G, Remschmidt H: Behandlungsergebnisse mit clozapin bei schizophrenen Jugendlichen. Z Kinder-Jugendpsychiat 14: 245–257, 1986.

    CAS  Google Scholar 

  34. Birmaher B, Baker R, Kapur S, et al: Clozapine for the treatment of adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 31: 160–164, 1992.

    PubMed  CAS  Google Scholar 

  35. McClellan JM, Werry JS: Schizophrenia, in Shaffer D (ed): The Psychiatric Clinics of North America. Philadelphia, WB Saunders 1992, vol 15, pp 131–148.

    Google Scholar 

  36. Werry JS, McClellan JM, Chard L: Childhood and adolescent schizophrenic, bipolar, and schizoaffective disorders: A clinical and outcome study, J Am Acad Child Adolesc Psychiatry 30: 457–465, 1991.

    PubMed  CAS  Google Scholar 

  37. Goodwin FK, Jamison KR: Manic-Depressive Illness. London, Oxford University Press, 1990.

    Google Scholar 

  38. Loranger AW, Levine PM: Age at onset of bipolar affective illness. Arch Gen Psychiatry 35: 1345–1348, 1978.

    PubMed  CAS  Google Scholar 

  39. Carlson GA: Child and adolescent mania: Diagnostic considerations. J Child Psychol Psychiatry 31: 331–341, 1990.

    PubMed  CAS  Google Scholar 

  40. Shopsin B, Gershon S, Thompson H, et al: Psychoactive drugs in mania. A controlled comparison of lithium carbonate, chlorpromazine, and haloperidol. Arch Gen Psychiatry 32: 34–42, 1975.

    PubMed  CAS  Google Scholar 

  41. Campbell M, Gonzalez NM, Silva RR: The pharmacologic treatment of conduct disorders and rage outbursts, in Shaffer D (ed): The Psychiatric Clinics of North America. Philadelphia, WB Saunders, 1992, vol 15, pp 69–85.

    Google Scholar 

  42. Cunningham MA, Pillai V, Rogers WJB: Haloperidol in the treatment of children with severe behavioural disorders. Br J Psychiatry 114: 845–854, 1968.

    PubMed  CAS  Google Scholar 

  43. Werry JS, Aman MG, Lampen E: Haloperidol and methylphenidate in hyperactive children. Acta Paedopsychiatr 42: 26–40, 1975.

    Google Scholar 

  44. Campbell M, Small AM, Green WH, et al: Behavioral efficacy of haloperidol and lithium carbonate: A comparison in hospitalized aggressive children with conduct disorder. Arch Gen Psychiatry 41: 650–656, 1984.

    PubMed  CAS  Google Scholar 

  45. Greenhill LL, Barmack JE, Spalten D, et al: Molindone hydrochloride in the treatment of aggressive, hospitalized children. Psychopharmacol Bull 17: 125–127, 1981.

    PubMed  CAS  Google Scholar 

  46. Greenhill LL, Solomon M, Pleak R, et al: Molindone hydrochloride treatment of hospitalized children with conduct disorder. J Clin Psychiatry 46: 20–25, 1985.

    PubMed  CAS  Google Scholar 

  47. Children’s Psychiatric Rating Scale (CPRS). Psychopharmacol Bull 21(4): 765–770, 1985.

    Google Scholar 

  48. Wong GH, Cock RJ: Long-term effects of haloperidol on severely emotionally disturbed children. Aust NZ J Psychiatry 5: 296–300, 1971.

    CAS  Google Scholar 

  49. Werry JS, Aman MG: Methylphenidate and haloperidol in children: Effects on attention, memory and activity. Arch Gen Psychiatry 32: 790–795, 1975.

    PubMed  CAS  Google Scholar 

  50. Platt JE, Campbell M, Green WH, et al: Cognitive effects of lithium carbonate and haloperidol in treatment-resistant aggressive children. Arch Gen Psychiatry 41: 657–662, 1984.

    PubMed  CAS  Google Scholar 

  51. Fish B, Shapiro T, Campbell M: Long-term prognosis and the response of schizophrenic children to drug therapy: A controlled study of trifluoperazine. Am J Psychiatry 123: 32–39, 1966.

    PubMed  CAS  Google Scholar 

  52. Campbell M, Anderson LT, Meier M, et al: A comparison of haloperidol, behavior therapy and their interaction in autistic children. J Am Acad Child Psychiatry 17: 640–655, 1978.

    PubMed  CAS  Google Scholar 

  53. Anderson LT, Campbell M, Grega DM, et al: Haloperidol in the treatment of infantile autism: Effects on learning and behavioral symptoms. Am J Psychiatry 141: 1195–1202, 1984.

    PubMed  CAS  Google Scholar 

  54. Anderson LT, Campbell M, Adams P, et al: The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. J Autism Dev Disord 19: 227–239, 1989.

    PubMed  CAS  Google Scholar 

  55. Naruse H, Nagahata M, Nakane Y, et al: A multicenter double-blind trial of pimozide (Orap), haloperidol and placebo in children with behavioral disorders, using crossover design. Acta Paedopsychiatr 48: 173–184, 1982.

    PubMed  CAS  Google Scholar 

  56. Cohen IL, Campbell M, Posner D, et al: Behavioral effects of haloperidol in young autistic children: An objective analysis using a within-subjects reversal design. J Am Acad Child Psychiatry 19: 665–677, 1980.

    PubMed  CAS  Google Scholar 

  57. Campbell M: Pharmacotherapy in early infantile autism. Biol Psychiatry 10: 399–423, 1975.

    PubMed  CAS  Google Scholar 

  58. Campbell M, Schopler E (co-chairpersons): Pervasive developmental disorders, in: Karasu TB (chairperson): Treatments of Psychiatric Disorders: A Task Force Report. Washington DC, American Psychiatric Association Press, 1989, vol 1, pp 179–294.

    Google Scholar 

  59. Tarjan C, Lowery VE, Wright SW: Use of chlorpromazine in two hundred seventy-eight mentally deficient patients. AMA J Disturbed Child 94: 294–300, 1957.

    CAS  Google Scholar 

  60. Pregelj S, Barkauskas A: Thioridazine in the treatment of mentally retarded children. A four-year retroactive evaluation. J Can Psychiatr Assoc 12: 213–215, 1967.

    CAS  Google Scholar 

  61. Freeman RD: Psychopharmacology and the retarded child, in Menolascino F (ed): Psychiatric Approaches to Mental Retardation. New York, Basic Books, 1970, pp 294–368.

    Google Scholar 

  62. Campbell M, Fish B, Shapiro T, et al: Thiothixene in young disturbed children: A pilot study. Arch Gen Psychiatry 23: 70–72, 1970.

    PubMed  CAS  Google Scholar 

  63. Campbell M, Fish B, Shapiro T, et al: Study of molindone in disturbed preschool children. Curr Ther Res 13: 28–33, 1971.

    PubMed  CAS  Google Scholar 

  64. Locascio JJ, Malone RP, Small AS, et al: Factors related to haloperidol response and dyskinesias in autistic children. Psychopharmacol Bull 27(2): 119–126, 1991.

    PubMed  CAS  Google Scholar 

  65. Rett A: Über ein eingenartiges hirntrophisches Syndrome bei Hyperammonamie in Kindersalter. Wien Med Wochenschr 166: 723–738, 1966.

    Google Scholar 

  66. Perry R, Campbell M, Adams P, et al: Long-term efficacy of haloperidol in autistic children: Continuous versus discontinuous drug administration. J Am Acad Child Adolesc Psychiatry 28: 87–92, 1989.

    PubMed  CAS  Google Scholar 

  67. Die Trill ML, Wolsky BB, Shell J, et al: Effects of long term haloperidol treatment on intellectual functioning in autistic children: A pilot study. Paper presented at the 31st Annual Meeting of the American Academy of Child Psychiatry, Toronto, October 10–14, 1984.

    Google Scholar 

  68. Shell J, Perry R, Adams P, et al: Effects of long-term haloperidol treatment on intellectual functioning in autistic children. Paper presented at the 34th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Washington, DC, October 21–25, 1987.

    Google Scholar 

  69. Borison RL, Ang L, Chang S, et al: New pharmacological approaches in the treatment of Tourette syndrome, in Friedhoff AJ, Chase TN (eds): Gilles de la Tourette Syndrome. New York, Raven Press, 1982, pp 377–382.

    Google Scholar 

  70. Shapiro E, Shapiro AK, Fulop G, et al: Controlled study of haloperidol, pimozide, and placebo for the treatment of Gilles de la Tourette’s syndrome. Arch Gen Psychiatry 46: 722–730, 1989.

    PubMed  CAS  Google Scholar 

  71. Bruun RD: Subtle and underrecognized side effects of neuroleptic treatment in children with Tourette’s Disorder. Am J Psychiatry 145: 621–624, 1988.

    PubMed  CAS  Google Scholar 

  72. Campbell M, Malone RP: Mental retardation and psychiatry disorders. Hosp Community Psychiatry 42: 374–379, 1991.

    PubMed  CAS  Google Scholar 

  73. Aman MG, Singh NN: Psychopharmacology of the Developmental Disabilities. Berlin, Springer-Verlag, 1988, pp 1–28.

    Google Scholar 

  74. Gadow KD, Poling AG: Pharmacotherapy and Mental Retardation. Boston, College-Hill Press, 1988.

    Google Scholar 

  75. Aman MG, Singh NN: Pharmacological intervention, in Matson JL, Mulick JA (eds): Handbook of Mental Retardation, ed 2. New York, Pergamon Press, 1991, pp 347–372.

    Google Scholar 

  76. Intagliata J, Rimck C: Psychoactive drug use in public and community residential facilities for mentally retarded persons. Psychopharmacol Bull 21: 268–278, 1985.

    PubMed  CAS  Google Scholar 

  77. Aman MG: Drugs and learning in mentally retarded persons, in Burrows GD, Werry JS (eds): Advances in Human Psychopharmacology. Greenwich, Conn, JAI Press, 1984, vol 3, pp 121–163.

    Google Scholar 

  78. Aman MG, White AJ, Field C: Chlorpromazine effects on stereotypic and conditioned behaviour of severely retarded patients — A pilot study. J Ment Defic Res 28: 253–260, 1984.

    PubMed  Google Scholar 

  79. Aman MG, Marks RE, Turbott SH, et al: Clinical effects of methylphenidate and thioridazine in intellectually subaverage children. J Am Acad Child Adolesc Psychiatry 30(2): 246–256, 1991.

    PubMed  CAS  Google Scholar 

  80. Singh NN, Aman MG: Effects of thioridazine dosage on the behavior of severely mentally retarded persons. Am J Ment Defic 85: 580–587, 1981.

    PubMed  CAS  Google Scholar 

  81. White AJ, Aman MG: Pimozide treatment in disruptive severely retarded patients. Aust NZ J Psychiatry 19: 92–94, 1985.

    CAS  Google Scholar 

  82. Aman MG, Teehan CJ, White AJ, et al: Haloperidol treatment with chronically medicated residents: Dose effects on clinical behavior and reinforcement contingencies. Am J Ment Retard 95: 452–460, 1989.

    Google Scholar 

  83. Aman MG, White AJ: Thioridazine dose effects with reference to stereotypic behavior in mentally retarded residents. J Autism Dev Disord 18: 355–366, 1988.

    PubMed  CAS  Google Scholar 

  84. Claghorn JL: A double-blind comparison of haloperidol (Haldol) and thioridazine (Mellaril) in outpatient children. Curr Ther Res 14: 785–789, 1972.

    PubMed  CAS  Google Scholar 

  85. Aman MG, Singh NN: Manual for the Aberrant Behavior Checklist. East Aurora, NY, Slosson Educational Publications, 1986.

    Google Scholar 

  86. Goldberg JB, Kurland AA: Pimozide in the treatment of behavioral disorders of hospitalized adolescents. J Clin Pharmacol 14: 134–139, 1974.

    PubMed  CAS  Google Scholar 

  87. Aman MG, Marks RE, Turbott SH, et al: Methylphenidate and thioridazine in the treatment of intellectually subaverage children: Effects on cognitive-motor performance. J Am Acad Child Adolesc Psychiatry 30: 816–824, 1991.

    PubMed  CAS  Google Scholar 

  88. Sleator E, von Neumann A, Sprague R: Hyperactive children: A continuous long-term placebocontrolled follow-up. JAMA 229: 316–317, 1974.

    PubMed  CAS  Google Scholar 

  89. Werry JS, Weiss G, Douglas V, et al: Studies on the hyperactive child: III. The effect of chlorpromazine upon behavior and learning ability. J Am Acad Child Psychiatry 5: 292–312, 1966.

    PubMed  CAS  Google Scholar 

  90. Rapoport J, Abramson A, Alexander D, et al: Playroom observations on hyperactive children on medication. J Am Acad Child Psychiatry 10: 524–534, 1971.

    PubMed  CAS  Google Scholar 

  91. Aman MG: Drugs, learning and the psychotherapies, in Werry JS (ed): Pediatric Psychopharmacology: The Use of Behavior Modifying Drugs in Children. New York, Brunner/Mazel, 1978.

    Google Scholar 

  92. Baldasserini R: Drugs and the treatment of psychiatric disorders, in Gilman A, Rall TW, Nies AS (eds): Goodman-Gilman’s The Pharmacological Basis of Therapeutics, ed 8. New York, Maxwell/ McMillan, 1991, pp 383–437.

    Google Scholar 

  93. Mikkelson EJ, Detlor J, Cohen DJ: School avoidance and social phobia triggered by haloperidol in patients with Tourette’s disorder. Am J Psychiatry 138: 1572–1575, 1981.

    Google Scholar 

  94. Richardson MA, Haugland G, Craig TJ: Neuroleptic use, parkinsonian symptoms, tardive dyskinesia, and associated factors in child and adolescent psychiatric patients. Am J Psychiatry 148: 1322–1328, 1991.

    PubMed  CAS  Google Scholar 

  95. Kane JM, Jeste DV, Barnes TRE, et al: Tardive Dyskinesia: A Task Force Report. Washington, DC, American Psychiatric Association Press, 1991.

    Google Scholar 

  96. Owens DGC, Johnstone EC, Frith CD: Spontaneous involuntary disorders of movement: Their prevalence, severity and distribution in chronic schizophrenics with and without treatment with neuroleptics. Arch Gen Psychiatry 39: 452–461, 1982.

    PubMed  CAS  Google Scholar 

  97. Van Putten T, Mutalipassi LR, Malkin MD: Phenothiazine-induced decompensation. Arch Gen Psychiatry 30: 102–105, 1974.

    PubMed  Google Scholar 

  98. Van Putten T, May PRA, Marder SR: Akathisia with haloperidol and thiothixene. Arch Gen Psychiatry 41: 1036–1039, 1984.

    PubMed  Google Scholar 

  99. Delay J, Deniker P: Drug-induced extrapyramidal syndromes, in Vinken PJ, Bruyn GW (eds): Handbook of Clinical Neurology. Amsterdam, North-Holland Publishing Co, 1968, pp 248–266.

    Google Scholar 

  100. Rifkin A, Quitkin F, Klein DF: Akinesia. A poorly recognized drug-induced extrapyramidal behavioral disorder. Arch Gen Psychiatry 32: 672–674, 1975.

    Google Scholar 

  101. Campbell M, Cohen IL, Small AM: Drugs in aggressive behavior. J Am Acad Child Psychiatry 21: 107–117, 1982.

    PubMed  CAS  Google Scholar 

  102. Gardos G, Cole JO: Weight reduction in schizophrenia by molindone. Am J Psychiatry 134: 302–304, 1977.

    PubMed  CAS  Google Scholar 

  103. Simpson GM: APA Task Force on Sudden Death. Washington, DC, American Psychiatric Association Press, 1987.

    Google Scholar 

  104. Pope HG, Keck PE, McElroy SL: Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. Am J Psychiatry 143: 1227–1233, 1986.

    PubMed  Google Scholar 

  105. Silver JM, Yudofsky SC: Psychopharmacology and electroconvulsive therapy, in Talbott JA, Hales RE, Yudofsky SC (eds): The American Psychiatric Press Textbook of Psychiatry. Washington, DC, American Psychiatric Press, 1989, pp 767–843.

    Google Scholar 

  106. Levinson F, Simpson GM: Neuroleptic-induced extrapyramidal symptoms with fever. Arch Gen Psychiatry 43: 839–848, 1986.

    PubMed  CAS  Google Scholar 

  107. Geller B, Greydanus DE: Haloperidol-induced comatose state with hyperthermia and rigidity in adolescence: Two case reports with a literature review. J Clin Psychiatry 40: 102–103, 1979.

    PubMed  CAS  Google Scholar 

  108. Moyes D: Malignant hyperpyrexia caused by trimeprazine. Br J Anaesth 45: 1163–1164, 1973.

    PubMed  CAS  Google Scholar 

  109. Klein SK, Levinsohn MW, Blumer JL: Accidental chlorpromazine ingestion as a cause of neuroleptic malignant syndrome in children. J Pediatr 107(6): 970–973, 1985.

    PubMed  CAS  Google Scholar 

  110. Campbell M, Green WH, Deutsch SI (eds): Child and Adolescent Psychopharmacology. Beverly Hills, Sage Publications, 1985.

    Google Scholar 

  111. Villeneuve A: The rabbit syndrome: A peculiar extrapyramidal reaction. Can J Psychiatry 17: 69–72, 1972.

    Google Scholar 

  112. Campbell M, Adams P, Perry R, et al: Tardive and withdrawal dyskinesia in autistic children: A prospective study. Psychopharmacol Bull 24(2): 251–255, 1988.

    PubMed  CAS  Google Scholar 

  113. Campbell M, Grega DM, Green WH, et al: Neuroleptic-induced dyskinesias in children. Clin Neuropharmacol 6: 207–222, 1983.

    PubMed  CAS  Google Scholar 

  114. Perry R, Nobler MS, Campbell M: Case report: Tourette-like symptoms associated with chronic neuroleptic therapy in an autistic child. J Am Acad Child Adolesc Psychiatry 28: 93–96, 1989.

    PubMed  CAS  Google Scholar 

  115. Klawans HL, Nausieda PA, Goetz CC, et al: Tourette-like symptoms following chronic neuroleptic therapy, in Friedhoff AJ, Chase TN (eds): Advances in Neurology. New York, Raven Press, 1982.

    Google Scholar 

  116. Smith RE. Domino EF: Dystonic and dyskinetic reactions induced by H1 antihistaminic medication, in Fann WE, Smith RC, Davis JN, et al (eds): Tardive Dyskinesia: Research and Treatment. Jamaica, NY, Spectrum Publications, 1980, pp 325–332.

    Google Scholar 

  117. Thach BT, Chase TN, Bosman JF: Oral facial dyskinesia associated with prolonged use of antihistaminic decongestants. N Engl J Med 293: 486–487, 1975.

    PubMed  CAS  Google Scholar 

  118. Chadwick D, Reynolds EG, Marsden CD: Anticonvulsant induced dyskinesias. J Neurol Neurosurg Psychiatry 39: 1210–1218, 1979.

    Google Scholar 

  119. Gardos G, Cole JO, La Brie R: The assessment of tardive dyskinesia. Arch Gen Psychiatry 34: 1206–1212, 1977.

    PubMed  CAS  Google Scholar 

  120. Gerlach J: Pathophysiological mechanisms underlying tardive dyskinesia, in Casey D, Chase TN, Christensen DE, et al (eds): Dyskinesia — Research and Treatment (Psychopharmacology suppl 2). Berlin, Springer-Verlag, 1985, pp 99–103.

    Google Scholar 

  121. Kane JM, Smith JM: Tardive dyskinesia. Arch Gen Psychiatry 39: 473–481, 1982.

    PubMed  CAS  Google Scholar 

  122. Crane GE, Naranjo ER: Motor disorders induced by neuroleptics. Arch Gen Psychiatry 24: 178–184, 1971.

    Google Scholar 

  123. Gardos G, Cole J, Tarsy D: Withdrawal symptoms associated with antipsychotic drugs. Am J Psychiatry 135: 1321–1324, 1978.

    PubMed  CAS  Google Scholar 

  124. McAndrew JB, Case Q, Treffert DA: Effects of prolonged phenothiazine intake on psychotic and other hospitalized children. J Autism Child Schizophr 2: 75–91, 1972.

    PubMed  CAS  Google Scholar 

  125. Gualtieri CT, Quade D, Hicks RE, et al: Tardive dyskinesia and other clinical consequences of neuroleptic treatment in children and adolescents. Am J Psychiatry 141: 20–23, 1984.

    PubMed  CAS  Google Scholar 

  126. Engelhardt DM, Polizios P: Adverse effects of pharmacotherapy in childhood psychosis, in Lipton MA, DiMascio A, Killam KF (eds): Psychopharmacology: A Generation of Progress. New York, Raven Press, 1978.

    Google Scholar 

  127. Meiselas KD, Spencer EK, Oberfield R, et al: Differentiation of stereotypies from neurolepticrelated dyskinesias in autistic children. J Clin Psychopharmacol 9: 207–209, 1989.

    PubMed  CAS  Google Scholar 

  128. Owens DGC, Johnstone EC, Frith CD: Spontaneous involuntary disorders of movement: Their prevalence, severity and distribution in chronic schizophrenic with and without treatment with neuroleptics. Arch Gen Psychiatry 39: 452–461, 1982.

    PubMed  CAS  Google Scholar 

  129. Schooler NR, Kane JM: Research diagnoses for tardive dyskinesia (Letter to the editor). Arch Gen Psychiatry 39: 486–487, 1982.

    PubMed  CAS  Google Scholar 

  130. Campbell M, Locascio JJ, Choroco MC, et al: Stereotypies and tardive dyskinesia: Abnormal movements in autistic children. Psychopharmacol Bull 26(2): 260–266, 1990.

    PubMed  CAS  Google Scholar 

  131. Malone RP, Ernst M, Godfrey KA, et al: Repeated episodes of neuroleptic-related dyskinesias in autistic children. Psychopharmacol Bull 27(2): 113–117, 1991.

    PubMed  CAS  Google Scholar 

  132. Crane GE: Neuroleptics and their long-term effects on the central nervous system, in DeVeaugh-Geiss J (ed): Tardive Dyskinesia and Related Involuntary Movement Disorders. Boston, John Wright Publishing Co, 1982, pp 71–84.

    Google Scholar 

  133. McLean P, Casey DE: Tardive dyskinesia in an adolescent. Am J Psychiatry 135: 969–971, 1978.

    PubMed  CAS  Google Scholar 

  134. Green WH, Campbell M, Wolsky BB, et al: Effects of short and long term haloperidol administration on growth in young autistic children. Paper presented at the 31st Annual Meeting of the American Academy of Child Psychiatry, Toronto, October 10-14, 1984.

    Google Scholar 

  135. Hamill PVV, Drizd TA, Johnson CL, et al: NCHS Growth Charts, 1976. Monthly Vital Statistics Report, Health Examination Survey Data, National Center for Health Statistics Publication (HRA)76-1120, 25(3): 1–22, 1976.

    Google Scholar 

  136. Spencer EK, Campbell M: Schizophrenic children: Diagnosis, phenomenology and pharmacotherapy. Schizophr Bull 19: 1993 (in press).

    Google Scholar 

Download references

Author information

Author notes

  1. Monique Ernst M.D., Ph.D.

    Present address: Brain Imaging Section, Department of Health and Human Services, National Institutes of Health, Bethesda, Maryland, 20892, USA

Authors and Affiliations

  1. Department of Psychiatry, New York University Medical Center, New York, New York, 10016, USA

    Magda Campbell M.D., Nilda M. Gonzalez M.D., Monique Ernst M.D., Ph.D. & Raul R. Silva M.D.

  2. Emeritus Professor, University of Auckland, Auckland, New Zealand

    John S. Werry M.D.

Authors
  1. Magda Campbell M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nilda M. Gonzalez M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Monique Ernst M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Raul R. Silva M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. John S. Werry M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of Auckland, Auckland, New Zealand

    John S. Werry M.D. (Emeritus Professor of Psychiatry) (Emeritus Professor of Psychiatry)

  2. The Nisonger Center for Mental Retardation and Developmental Disabilities, The Ohio State University, Columbus, Ohio, USA

    Michael G. Aman Ph.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1993 Springer Science+Business Media New York

About this chapter

Cite this chapter

Campbell, M., Gonzalez, N.M., Ernst, M., Silva, R.R., Werry, J.S. (1993). Antipsychotics (Neuroleptics). In: Werry, J.S., Aman, M.G. (eds) Practitioner’s Guide to Psychoactive Drugs for Children and Adolescents. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-2884-5_10

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-2884-5_10

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-306-44389-3

  • Online ISBN: 978-1-4615-2884-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation